查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953649

女性健康照護市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物、應用、地區和競爭格局分類，2021-2031年

Women Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球女性保健市場預計將從 2025 年的 111.2 億美元成長到 2031 年的 156.9 億美元，複合年成長率為 5.91%。

該市場涵蓋專為治療、診斷和管理女性特有的生理和生殖系統疾病而設計的藥物、醫療設備和診斷服務。推動這一市場成長的關鍵因素包括慢性病和女性特有疾病的日益普遍，以及女性人口老化導致持續醫療干預需求增加。此外，政府加大對女性健康的投入以及更廣泛的保險報銷政策也對支撐產業需求和發展發揮著至關重要的作用。

市場概覽
預測期 2027-2031
市場規模：2025年 111.2億美元
市場規模：2031年 156.9億美元
複合年成長率：2026-2031年 5.91%
成長最快的細分市場 普羅利亞
最大的市場 北美洲

然而，市場擴張面臨的主要障礙是開發中國家診斷基礎設施和醫療保健服務取得的巨大差距。這種差距限制了關鍵醫療技術的有效推廣，並阻礙了快速成長地區疾病的早期發現。例如，根據美國癌症協會2024年的報告，全球僅有36%的女性接受過子宮頸癌篩檢。此類基礎設施不足和預防性醫療保健覆蓋率低是該領域公平分配和整體發展的重要障礙。

市場促進因素

政府主導的各項措施和對女性健康的投入不斷增加，是推動彌合醫學研究和醫療服務領域長期存在的性別差距的關鍵驅動力。公共部門機構正在啟動有針對性的項目，以支持子宮內膜異位症和更年期等疾病解決方案的商業化，並降低早期創新階段的風險。作為這項努力的象徵，美國國防高級研究計劃局（DARPA）的醫療部門ARPA-H於2024年10月宣布，已透過其「女性健康衝刺計畫」（津貼 for Women’s Health）撥款1.1億美元，資助23家Start-Ups，以加速從卵巢健康到心血管疾病等領域的研發。聯邦政府的這項支持凸顯了該領域的重要性，提供了彌合資金缺口所需的必要資金，並確保科學突破能夠轉化為可實際應用的醫療產品。

同時，女性健康科技和數位健康解決方案的快速發展正在重塑市場格局，它們提供便利、個人化和數據驅動的診療路徑。這些平台透過實現遠距專家諮詢和持續監測，正在革新生殖健康、生育治療和計劃生育管理。 2024年10月，Maven Clinic獲得1.25億美元的F輪資金籌措，用於拓展其生育和更年期支持平台。這體現了改善女性健康所帶來的經濟價值，並因此推動了私人投資的激增。根據2024年世界經濟論壇的報告，到2040年，解決女性健康差距問題每年可為全球經濟貢獻1兆美元。

市場挑戰

開發中國家診斷基礎設施嚴重不足，醫療服務取得受限，成為限制全球女性健康市場成長的一大瓶頸。這種結構性缺陷阻礙了醫療產品有效滲透到高需求地區，因為專業藥品和診斷設備需要基本的醫療設施才能投入使用。因此，企業在利用這些新興市場的潛在規模方面面臨挑戰，本應推動全球擴張的收入來源也停滯不前。

由於缺乏醫療服務，相當一部分女性患者仍未被診斷和治療，導致潛在市場規模不斷萎縮。根據世界經濟論壇2024年的數據，由於醫療服務體系的障礙，女性一生中約有25%的時間處於健康狀況不佳的狀態，而男性則沒有這種優勢。這項數據凸顯了市場機會的巨大損失，並表明無法及時為女性群體提供醫療干預與產業價值的損失和市場發展勢頭的受阻直接相關。

市場趨勢

人工智慧驅動的精準診斷技術的加速發展正從根本上改變市場格局，有效應對篩檢準確性和疾病早期檢測的關鍵挑戰。傳統的診斷框架往往忽略了性別間的生理差異，而開發人員正利用女性專屬資料集強化機器學習演算法的訓練，以提高乳癌和卵巢癌等疾病的影像診斷靈敏度。這項技術變革對於克服診斷有效性的製度性障礙，引領業界邁向高度個人化的醫療保健至關重要。根據 Lux Capital 2025 年 1 月發布的報告，2024 年全球人工智慧醫療保健市場規模將達到 208 億美元，但其在女性醫療保健領域的應用仍然有限，這意味著專業診斷解決方案在彌合這一差距方面擁有巨大的發展機會。

同時，隨著女性健康科技（Femtech）的範疇擴展至慢性非生殖系統疾病，市場關注點也從不孕不育和懷孕轉向解決長期慢性疾病。創新者正迅速開發針對以往未被充分重視、但對女性影響尤為嚴重的疾病的管理方案，例如自體免疫疾病、心血管疾病和慢性疼痛。這種多元化發展源於迫切需要應對那些限制女性就業和生活品質的健康負擔。正如Hologic於2024年12月發布的第四份年度全球女性健康指數報告所指出的，全球超過26%的女性表示存在影響其日常生活的健康問題，這意味著約有10億女性生活在未得到有效控制的身體機能障礙之中。而這些女性正是這一新興子部門所關注的治療對象。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球女性健康市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物特定資訊（EVISTA、XGEVA、Prolia、Mirena、 Zometa、Recrust/Aclarsta、Minastrinn 24 Fe、Nuvaling、Forteo、Premarin、Actonel、ORTHO TRI-CY LO (28)）
    • 依用途分類（荷爾蒙不孕症、停經後骨質疏鬆症、子宮內膜異位症、避孕、更年期症狀、卵巢症候群、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美女性醫療保健市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲女性醫療保健市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區女性健康市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲女性醫療保健市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲女性醫療保健市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球女性健康市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Cardinal Health
  • Allergan plc.
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Agile Therapeutics Inc.
  • Ferring Pharmaceuticals
  • Mylan NV
  • Lupin Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23238

The Global Women Healthcare Market is projected to expand from USD 11.12 Billion in 2025 to USD 15.69 Billion by 2031, reflecting a CAGR of 5.91%. This market comprises pharmaceuticals, medical devices, and diagnostic services specifically designed to treat, diagnose, and manage physical and reproductive conditions inherent to women. Key drivers propelling this growth include the increasing prevalence of chronic and gender-specific diseases, alongside an aging female population that requires sustained medical intervention. Additionally, rising government investments in female health initiatives and broader insurance reimbursement policies are playing a fundamental role in supporting industry demand and development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.12 Billion
Market Size 2031USD 15.69 Billion
CAGR 2026-20315.91%
Fastest Growing SegmentProlia
Largest MarketNorth America

However, a major obstacle impeding market expansion is the profound disparity in diagnostic infrastructure and healthcare access within developing nations. This gap restricts the effective reach of essential medical technologies and hinders timely disease detection in high-growth regions. For instance, the American Cancer Society reported in 2024 that only 36% of women globally had been screened for cervical cancer. Such infrastructural deficiencies and low rates of preventative care constitute significant barriers to the equitable penetration and overall growth of the sector.

Market Driver

Increasing government initiatives and funding for women's health are serving as critical drivers, effectively mobilizing resources to close historical gender gaps in medical research and care delivery. Public sector agencies are launching targeted programs to de-risk early-stage innovations and support the commercialization of solutions for conditions like endometriosis and menopause. Highlighting this commitment, the Advanced Research Projects Agency for Health announced in October 2024 that it had allocated $110 million to 23 startups through its 'Sprint for Women's Health' awards to accelerate developments in areas ranging from ovarian health to cardiovascular disease. This federal support validates the sector and provides the capital necessary to bridge funding gaps, ensuring scientific breakthroughs become accessible medical products.

Simultaneously, the rapid adoption of FemTech and digital health solutions is reshaping the market by delivering convenient, personalized, and data-driven care pathways. These platforms are revolutionizing the management of reproductive health, fertility, and family planning by enabling remote specialist access and continuous monitoring. In October 2024, Maven Clinic secured $125 million in Series F funding to expand its fertility and menopause benefit platforms, demonstrating the surge in private investment driven by the economic value of improved female health outcomes. According to the World Economic Forum in 2024, addressing the women's health gap could potentially contribute an additional $1 trillion annually to the global economy by 2040.

Market Challenge

The severe disparity in diagnostic infrastructure and limited healthcare access within developing nations creates a substantial bottleneck that specifically curbs the growth of the global women's healthcare market. This structural deficiency hinders the effective penetration of medical products into high-demand regions, as specialized pharmaceuticals and diagnostic devices rely on foundational medical facilities for deployment. Consequently, companies face challenges in capitalizing on the volume potential of these emerging markets, leading to stagnated revenue streams that would otherwise fuel global expansion.

This lack of accessibility results in a significant portion of the female population remaining undiagnosed and untreated, which reduces the effective total addressable market. Data from the World Economic Forum in 2024 indicates that women spent approximately 25% more of their lives in poor health compared to men due to systemic barriers in care delivery. This statistic underscores the magnitude of the missed market opportunity, as the inability to provide timely medical intervention to this demographic directly correlates with lost industry value and suppressed market momentum.

Market Trends

The acceleration of AI-enabled precision diagnostics is fundamentally transforming the market by addressing critical gaps in screening accuracy and early disease detection. While traditional diagnostic frameworks often overlook sex-specific physiological nuances, developers are increasingly training machine learning algorithms on female-specific datasets to improve imaging sensitivity for conditions such as breast and ovarian cancer. This technological shift is essential for overcoming systemic barriers in diagnostic efficacy and moving the industry toward highly individualized care. According to a January 2025 report by Lux Capital, while the global AI healthcare market was valued at $20.8 billion in 2024, its application in women's health remains limited, signaling a massive opportunity for specialized diagnostic solutions to bridge this disparity.

At the same time, the expansion of FemTech into non-reproductive chronic conditions is widening the market's focus beyond fertility and pregnancy to address debilitating long-term illnesses. Innovators are rapidly developing management solutions for autoimmune diseases, cardiovascular health, and chronic pain disorders, which disproportionately affect women yet have been historically under-addressed. This diversification is driven by the urgent need to manage health burdens that restrict female workforce participation and quality of life. As noted in Hologic's December 2024 'Global Women's Health Index Year 4 Global Report', over 26% of women worldwide reported health problems that prevented them from normal daily activities, representing nearly 1 billion women living with unmanaged physical limitations that this expanding sub-sector aims to treat.

Key Market Players

  • Bayer AG
  • Cardinal Health
  • Allergan plc.
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Agile Therapeutics Inc.
  • Ferring Pharmaceuticals
  • Mylan N.V.
  • Lupin Limited

Report Scope

In this report, the Global Women Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Women Healthcare Market, By Drug

  • EVISTA
  • XGEVA
  • Prolia
  • Mirena
  • Zometa
  • Reclast/Aclasta
  • Minastrin 24 Fe
  • NuvaRing
  • FORTEO
  • Premarin
  • ACTONEL
  • ORTHO TRI-CY LO (28)

Women Healthcare Market, By Application

  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome
  • Others

Women Healthcare Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Women Healthcare Market.

Available Customizations:

Global Women Healthcare Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Women Healthcare Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, ORTHO TRI-CY LO (28))
    • 5.2.2. By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Women Healthcare Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Women Healthcare Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Women Healthcare Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Women Healthcare Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By Application

7. Europe Women Healthcare Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Women Healthcare Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By Application
    • 7.3.2. France Women Healthcare Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Women Healthcare Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Women Healthcare Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Women Healthcare Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By Application

8. Asia Pacific Women Healthcare Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Women Healthcare Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By Application
    • 8.3.2. India Women Healthcare Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Women Healthcare Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Women Healthcare Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Women Healthcare Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By Application

9. Middle East & Africa Women Healthcare Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Women Healthcare Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Women Healthcare Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Women Healthcare Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By Application

10. South America Women Healthcare Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Women Healthcare Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Women Healthcare Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Women Healthcare Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Women Healthcare Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cardinal Health
  • 15.3. Allergan plc.
  • 15.4. Merck & Co.
  • 15.5. Pfizer Inc.
  • 15.6. Amgen Inc.
  • 15.7. Agile Therapeutics Inc.
  • 15.8. Ferring Pharmaceuticals
  • 15.9. Mylan N.V.
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer